Global Antiulcerant Drugs Market: Overview
Antiulcerant drugs are a wide class of
drugs used in treating ulcers of the stomach and intestine. Some of the
popular antiulcerant drugs used currently are H2 receptor antagonists,
gastric mucosal protective drugs, antacids, and antibiotics. They are
also used as proton pump inhibitors as co-treatment in patients with the
risk of gastrointestinal bleeding events such as those taking aspirin.
Their use prevents the production of gastric acid by stomach and lower
part of abdomen. The rising instance of heartburn and indigestion caused
by the production of excess stomach acid has helped antiulcerant drugs
occupy significant role in the treatment of stomach ulcers. Some
antiulcerant drugs are also gaining popularity in the treatment of
diarrhea or address an irritable gastrointestinal tract in patients.
The various evaluations of the growth dynamics of the global antiulcerant drugs market will offer insights and projections for emerging as well as new entrants to help them tap into lucrative avenues. The assessments can guide interested participants to know recent investment of prominent players on research and development of new drugs.
Global Antiulcerant Drugs Market: Trends and Opportunities
There has been rising awareness about
ulcer diseases, which has been imparting an increasing momentum to the
evolution of the antiulcerant drugs market. The pipeline of promising
antiulcerant drugs has been rising over the past few years in various
parts of the world. In recent years, the pharmacology of antiulcerant
drugs has received considerable attention by pharmaceutical companies,
which has helped them develop drugs with better clinical results. The
rising incidence of peptide ulcers, especially in people with sedentary
lifestyle, is also catalyzing the growth of the global antiulcerant
drugs market. The rising acceptance of antacids in anti-ulcer agents
among the patient population for symptomatic relief is also a
significant boosting the market.
There is prevalence of infection with H. pylori in communities with the lack of access to clean water and proper sewage systems. This if untreated may lead to peptic ulcer disease, and antiulcerant drugs play crucial role in the treatment. The growing mortality of thrombotic events, especially in tuberculosis patients, is also likely to accentuate prospects of the antiulcerant drugs market in the coming few years. The rising risk of adverse cardiovascular events related to patients treated with aspirin has fueled the uptake of antiulcerant drugs. In recent years, several pharmaceuticals have been actively working to adopt advanced technologies for manufacturing anatacids. Moreover, they are spending sizeable sums on accelerating their drug pipelines. This will open new, exciting avenues in the global market.
Global Antiulcerant Drugs Market: Regional Outlook
The report on the global antiulcerant
drugs market offers a critical assessment of key regional growth
dynamics and lucrative avenues in emerging markets. The study also
assesses the growth potential of these regions and the trends that will
fuel their expansion over the next few years. Regionally, developed
regions, notably North America, might generate copious amounts of
revenue to the global antiulcerant drugs market. The trend will be
supported by the substantial uptake of advanced drug manufacturing
technologies in the regions. On the other hand, Asia Pacific is one of
the regions that show great potential in the near future. One of the
several factors that may contribute to the rising demand for
antiulcerant drugs in the region is the growing prevalence of diabetes.
Global Antiulcerant Drugs Market: Competitive Landscape
The study takes a closer look at recent
strategies and drug development initiatives made by various players in
the global antiulcerant drugs market. It also highlights major
investment measures taken by established players. Some of the prominent
companies in the antiulcerant drugs market are Takeda Pharmaceutical,
Eisai, Daewoong Pharmaceutical, Allergan, and AstraZeneca plc.
No comments:
Post a Comment